and bm11@sanger.ac.uk 2 Summary: Tumors subvert immune cell function to evade immune responses 1 . The mechanisms of tumor immune evasion are incompletely understood. Here we show that tumors induce de novo steroidogenesis in T lymphocytes to evade antitumor immunity. Using a novel transgenic fluorescent reporter mouse line we identify and characterize de novo steroidogenic T cells. Genetic ablation of T cell steroidogenesis restricts experimental primary tumor growth and metastatic dissemination. Steroidogenic T cells dysregulate anti-tumor immunity that can be restored by inhibiting the steroidogenesis pathway. The study demonstrates that T cell de novo setroidogenesis is a cause of anti-tumor immunosuppression and a druggable target.
Summary:
Tumors subvert immune cell function to evade immune responses 1 Steroidogenesis is a metabolic process by which cholesterol is converted to steroids 2 .
The biosynthesis of steroids starting from cholesterol is often termed as "de novo steroidogenesis" 1 . Cytoplasmic cholesterol is transported into the mitochondria where the rate-limiting enzyme CYP11A1 (also known as P450 side chain cleavage enzyme) converts it to pregnenolone, the first bioactive steroid of the pathway and precursor of all other steroids ( Figure 1a) 2, 3 . The steroidogenesis pathway has been extensively studied in adrenal gland, gonads and placenta. De novo steroidogenesis by other tissues, known as "extraglandular steroidogenesis", in brain 2,4,5 , skin 6 , thymus 7 , and adipose tissues 8 has also been reported. However the (patho)physiological role of extraglandular steroidogenesis is largely unknown 3 .
Steroid hormones are known immunosuppressive biomolecules 9, 10 . We recently reported that CD4 + T cells induce de novo steroidogenesis to restore immune homeostasis by limiting the immune response against a worm parasite 11 . In cancer, the immunosuppressive tumor microenviroenmnt (TME) prevents immune cells from mounting an effective anti-tumor immune reposne 1 . Thus we sought to determine if T cell steroidogensis could contribute to the generation of a suppressive niche in the TME.
Cyp11a1 expression is a faithful biomarker of de novo steroidogenesis 2 , thus we generated a novel reporter mouse line to identify Cyp11a1-expressing steroidogenic cells definitively (Figure 1b , c, Extended Data Figure 1a , b, c and d). As expected, mCherry expression was detected in single cell suspensions of testis and adrenal glands but not in the spleen (Figure 1c ) or other tissues such as lung, kidney, blood, liver, bone marrow, lymph nodes and thymocytes (Extended Data Figure 1b ).
However, upon activation in vitro, Cyp11a1-mCherry signal was detected specifically in activated type-2 CD4 + helper T cells (i.e. Th2 cells) (Extended Data Figure 1c ) as reported previously 11 . Cyp11a1 expression was only detectable in mCherry expressing T helper cells but not in the mCherry negative T helper cells (Extended Data Figure 1d ). Exploiting this Cyp11a1-mCherry reporter line, we determined the ability of a panel of cytokines commonly found in inflammatory settings including the tumors to induce steroidogenesis. IL6, TSLP, IL13, and IL4 induced a strong induction of Cyp11a1-mCherry in CD4 + T cells that had also been activated by anti-CD3 and anti-CD28. In contrast, IL12 had minimal effect on steroidogenesis ( Figure   1d , Extended Data Figure 2a and b). This result indicates that not only the Th2 but also other T cell types are capable of de novo steroidogenesis. To test this, we differentiated naïve CD4 + or CD8 + T cells into Th1, Th2, Th9, Th17, Tfh, Treg, Tc1 and Tc2 subsets in vitro. All subsets examined, with the exception of Th1 and Tc1 exhibited Cyp11a1-mCherry expression when stimulated (Figure 1e , Extended Data Figure 2c ). However, Th2 cells showed the greatest potential to express Cyp11a1.
Tumor infiltrating T cells are key fate determinants within a tumor, but are often suppressed 12 . The steroidogenesis-inducing cytokines examined above are also often present in the TME 13, 14 , thus we next sought to examine the steroidogenic capacity of T cells infiltrating tumors, and their impact on tumor development. First, to explore Cyp11a1 expression in vivo we utilized the well-established B16-F10 melanoma model [15] [16] [17] and generated subcutaneously implanted tumors in Cyp11a1-mCherry reporter mice. Cyp11a1 expression was detected in immune cells of primary tumor tissue, but not in tumor-draining brachial lymph nodes (LN) or blood (Figure 2a ), indicating that stimulation occurs in situ. Within the tumor, Cyp11a1 + tumor infiltrating T cells were predominantly CD4 + (Figure 2b ). We next measured the functional output of Cyp11a1 expression. Significant concentrations of the steroid pregnenolone were detected exclusively in immune cells isolated from tumors, with negligible levels detected in cells from the spleen (Figure 2c ). Using the B16-F10 model of experimental metastatic dissemination 18 , we determined that lungs with metastatic nodules, but not control lungs without metastatic nodules, had elevated levels of pregnenolone ( Figure 2d ).
Having observed steroidogenic T cells in murine melanoma, we turned to publicly available transcriptomic data sets to verify our findings and ascertain relevance in the human setting. CYP11A1 mRNA expression, and thus steroidogenic potential, was identified in a range of cancer types including liver, breast, prostate, lung, kidney, sarcoma, glioma, uterine, cervical, lymphoma and melanoma (Figure 2e Topical application of pregnenolone at the primary tumor site was sufficient to compensate for the Cyp11a1 deficiency, restoring tumor growth to levels comparable with control mice (Figure 3d ). Furthermore, pharmacological inhibition of Cyp11a1 by aminoglutethimide (AG) recapitulated the tumor restriction phenotype of Cyp11a1 genetic deletion ( Figure 3e ). Together, these data indicate that, T cell derived steroids can support tumor growth.
It has been reported that steroid hormones induce immunosuppressive M2 phenotype in macrophages 9,21 , cell death and anergy in T cells 9 and tolerance in dendritic cells 9 22 .
Therefore we set out to test whether steroidogenic T cells support tumor growth through the induction of immunosuppressive phenotypes in infiltrating immune cells.
To determine whether intratumoral macrophages were M1 or M2 type, we purified tumor infiltrating macrophages (Lin-CD45 + CD11b + ) and analyzed mRNA expression Altogether these data suggest that inhibition of T cell steroidogenesis reinstates the anti-tumor immunity.
The importance of systemic steroid hormones is well documented in regulating cell metabolism and immune cell function in homeostasis, but the role of local cell type specific steroidogenesis is less clear, particularly in pathologies such as cancer. This is in part due to the lack of tools to study steroidogenesis in a tissue-specific manner in vivo. To circumvent this we generated two novel Cyp11a1-mCherry reporter and conditional Cyp11a1 knockout mice to identify de novo steroidogenic cells and study their in vivo role respectively. Using these two discovery tools, we uncovered a novel anti-tumor immune suppression mechanism that may be exploited clinically to reinstate the anti-tumor immunity ( Figure 4g ).
Materials and Methods

Mice
The care and use of all mice in this study were in accordance with the UK Animals in EDTA was added to all samples to neutralize collagenase activity (final concentration (5mM) and digested tissues were passed through 70µm filters (Falcon).
Cell sorting
Once processed, single cell suspension tumour samples were incubated with a fixable fluorescent viability stain (Life Technologies) for 20mins (diluted 1:1000 in PBS) prior to incubation with conjugated primary antibodies for 30 mins at 4 0 C. Antibodies were diluted in PBS 0.5% BSA. Stained samples were sorted, using the MoFlo XDP cytometer system.
T helper Cell Culture
Splenic naïve T helper cells from Cyp11a1-mCherry reporter mice were purified with the CD4 + CD62L + T Cell Isolation Kit II (Miltenyi Biotec) and polarized in vitro toward differentiated Th1, Th2, Th9, Th17, iTreg and Tfh subtype as described previously (Pramanik J et al, 2018) 28 . In brief, naïve cells were seeded into anti-CD3e
(2 µg/ml, clone 145-2C11, eBioscience) and anti-CD28 (5 µg/ml, clone 37.51, eBioscience) coated plates. The medium contained the following cytokines and/or antibodies: with monensin (2µM, eBioscience) for the last 3 hrs.
In vitro Tc1 and Tc2 differentiation
Splenic naïve CD8 + T cells were purified by using Naive CD8a + T Cell Isolation Kit, mouse (Miltenyi Biotec) following manufacturers protocol, and polarized in vitro toward differentiated Tc1 and Tc2. In brief, naive cells were seeded into anti-CD3e (2 µg/ml, clone 145-2C11, eBioscience) and anti-CD28 (5 µg/ml, clone 37.51, eBioscience) coated plates. The medium contained the following cytokines and/or antibodies:
Tc1 subtype: Recombinant murine IL2 (10 ng/ml, R&D Systems), recombinant murine IL12 (10 ng/ml, R&D Systems) and neutralizing anti-IL4 (10µg/ml, clone 11B11, eBioscience). Tc2 subtype: Recombinant murine IL2 (10 ng/ml, R&D Systems), recombinant murine IL-4 (10 ng/ml, R&D Systems) and neutralizing anti-IFNg (10µg/ml, clone XMG1.2, eBioscience).
Quantitative PCR (qPCR)
Tumor infiltrating macrophages (Lin-CD11b+) and CD8 + T cells were purified by cell sorting. We used Cells-to-C T kit (Invitrogen/Thermofisher Scientific) and followed 
Western Blot Antibodies
Anti-CYP11A1 (Santa Cruz Biotechnology, C-16) and anti-TBP (Abcam) were used.
Quantitative ELISA CD45 + leukocytes were purified from B16-F10 tumor masses and lungs, of mice that had been tail vein administered B16-F0 cells, and seeded at equal density in IMDM medium supplemented with 10% charcoal stripped fetal bovine serum (Life Technologies, Invitrogen) for 24 hrs. Pregnenolone concentrations of the culture supernatants were quantified using pregnenolone ELISA kit (Abnova) and corticosteroids ELISA (Thermofisher) kit following manufacturer's instruction.
Absorbance was measured at 450 nm, and data were analyzed in GraphPad Prism 5.
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